Mechanism of action of anti-HER2 monoclonal antibodies

Related Experiment Video

Updated: Oct 4, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

J Baselga1, J Albanell

  • 1Medical Oncology Service, Hospital General Universitari Vall d'Hebron, Barcelona, Spain. beselga@hg.vhebron.es

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 28, 2001
PubMed

Insights

Trastuzumab (Herceptin) is a targeted therapy for HER2-positive breast cancer. This review details its complex mechanisms, including HER2 downregulation and immune response induction, aiding treatment selection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Novel biologic agents are emerging for cancer treatment.
  • Trastuzumab (Herceptin) is a humanized monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2).
  • HER2 overexpression in 20%-30% of breast cancers correlates with aggressive disease.

Purpose of the Study:

  • To review the current knowledge on trastuzumab's mechanism of action.
  • To explore the complex pathways involved in trastuzumab's efficacy.
  • To consider the implications for selecting concomitant chemotherapy.

Main Methods:

  • Review of existing literature on trastuzumab's biological effects.
  • Analysis of HER2 signaling pathways and trastuzumab's interactions.
  • Examination of clinical data regarding trastuzumab's impact.

Main Results:

  • Trastuzumab induces HER2 protein downregulation and prevents HER2-containing heterodimer formation.
  • It initiates G1 arrest, induces p27, and prevents HER2 cleavage.
  • Trastuzumab inhibits angiogenesis and triggers immune-mediated mechanisms.

Conclusions:

  • Trastuzumab's multifaceted mechanism of action is crucial for its efficacy in HER2-positive metastatic breast cancer.
  • Understanding these mechanisms aids in optimizing combination chemotherapy strategies.
  • Trastuzumab represents a significant advancement in oncogene-targeted cancer therapy.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antibody Structure and Classes01:25

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...